2 results match your criteria: "the Legorreta Cancer Center at Brown University and Brown University Health[Affiliation]"
Molecular testing in urinary cytology specimens: Current status and future directions.
Urol Oncol
March 2025
Department of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, the Legorreta Cancer Center at Brown University and Brown University Health, Providence, RI.
Bladder cancer is a common type of urological cancer with high recurrence and mortality rates. Currently, it is diagnosed and monitored using minimal invasive cystoscopies and biopsies. Urinary cytology, the most widely accepted noninvasive and more economic urinary diagnosis method, aims to detect high grade urothelial carcinoma with a high specificity but low sensitivity, especially for detecting low-grade tumors.
View Article and Find Full Text PDFTFE3-rearranged nonmelanotic renal PEComa: a case series expanding their phenotypic and fusion landscape.
Histopathology
November 2024
Diagnostic and Molecular Pathology, Alberta Precision Laboratories and University of Calgary, Calgary, AL, Canada.
Article Synopsis
- This study investigates the characteristics of 10 rare primary renal perivascular epithelioid cell tumors (PEComas) that have a specific genetic alteration (Xp11.2 translocation), focusing on their presentation and outcomes.
- The patient group included both genders aged 14-65, with positive outcomes for most after surgical treatment, and showed consistent expression of certain markers (TFE3 being the most significant) while lacking others typically seen in similar tumors.
- The findings reveal the genetic variety among these tumors, with unique TFE3 fusion partners identified, and emphasize the importance of TFE3 immunohistochemistry for diagnosis and differentiation from other kidney cancers.